Ons EGFR: Epidermal growth factor receptor; TKI: Tyrosine kinase inhibitor; FISH: Fluorescence in situ hybridization;

Ons EGFR: Epidermal growth factor receptor; TKI: Tyrosine kinase inhibitor; FISH: Fluorescence in situ hybridization; PI3KCA: Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform; EMT: Epithelialto-mesenchymal transition; NSCLC: Non-small cell lung cancer; SCLC: Modest cell lung cancer; TTF-1: Thyroid transcription issue 1; PFS: Progression-free survival; OS: All round survival.Ji et al. BMC Cancer 2013, 13:606 http://biomedcentral/1471-2407/13/Page eight of11.12.13.14.15.16.17.18.19.20.21.22.23.24. 25.epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28(two):35760. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, et al: Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009, 4(11):e7887. Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjos S, Hoivik EA, Wik E, Halle MK, Oyan AM, et al: High-throughput mutation profiling of principal and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be often mutated. PLoS One 2012, 7(12):e52795. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, et al: High-throughput mutation profiling identifies frequent somatic mutations in sophisticated gastric adenocarcinoma. PLoS 1 2012, 7(six):e38892. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, H1 Receptor Inhibitor Storage & Stability Miller VA, Ladanyi M: Rebiopsy of lung cancer sufferers with acquired resistance to EGFR inhibitors and enhanced detection from the T790M mutation applying a locked nucleic acid-based assay. Clin Cancer Res 2011, 17(5):1169180. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, et al: Rapid targeted mutational analysis of human tumours: a clinical platform to guide customized cancer medicine. EMBO Mol Med 2010, 2(5):14658. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, et al: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer individuals with EGFR mutations. Clin Cancer Res 2011, 17(five):1160168. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, et al: Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29(16):2346356. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct organic history of individuals with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17(six):1616622. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W: New approaches in overcoming acquired resistance to epidermal development issue receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011, 17(17):5530537. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A: Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell varieties of adult mouse lung. Cancer Cell 2011, 19(six):75464. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, IL-6 Inhibitor MedChemExpress Naumov GN, Yeap BY, Jarrell E, Sun J, et al: Allelic dilution obscures detection of a biologically considerable resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006, 116(ten).